FDA
-
-
-
-
-
-
-
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
-
-
-
-
-
-
-
NILEMDO receives Health Canada approval for LDL cholesterol reduction
-
-
-
-
-
-
-
Esperion to Participate in Jefferies Global Healthcare Conference - London
-
-
-
-
-
-
-
Esperion announces public offering of common stock
-
-
-
-
-
-
-
Esperion to Participate in Upcoming September Investor Conferences
-
-
-
-
-
-
-
Esperion Appoints Craig Thompson to Board of Directors
-
-
-
-
-
-
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

